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Background and the purpose of the study: Adenosine deaminase (ADA) inhibition not only may be applied for
the treatment of ischemic injury, hypertension, lymphomas and leukaemia, but also they have been considered as
anti- inflammatory drugs. On the other hand according to literatures, ADA inhibitors without a nucleoside
framework would improve pharmacokinetics and decrease toxicity. Hence we have carried out a rational
pharmacophore design for non-nucleoside inhibitors filtration.
Methods: A merged pharmacophore model based on the most potent non-nucleoside inhibitor
erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and natural products were generated and applied for compounds
filtration. The effects of filtrated compounds based on pharmacophore and docking studies investigated on
ADA by UV and Fluorescence spectroscopy techniques.
Results: Extracted compounds were find efficiently inhibit ADA, and the most potent (2) shows an inhibition
constant equal to 20 μM. Besides, Fluorescence spectroscopy studies revealed that enzyme 3D structure bear
further change in lower concentrations of compound 2.
Conclusion: 3 non-nucleoside inhibitors for ADA are presented. According to obtained results from UV and
fluorescence spectroscopy, such interesting pharmacophore template with multiple approaches will help us to
extract or design compound with desired properties.
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Adenosine deaminase (ADA) is a key enzyme in the pur-
ine metabolism that hydrolyse adenosine to inosine irre-
versibly [1]. This path involves in RNA, DNA, ATP
synthesizes, and energy transitions reactions. This enzyme
also has been found in lymphoid systems like lymph
nodes, spleen and thymus [2]. Involvement of this enzyme
is clear in catabolytic paths and also its role in the protec-
tion of immune systems [3-5].
Over activity of ADA is associated with AIDS, leukemia,
stresses and Parkinson [6-8]. In addition, the high value of
ADA has been seen in rheumatoid arthritis [9]. Adenosine* Correspondence: amanlou@tums.ac.ir
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reproduction in any medium, provided the oras the substrate of ADA regulates many of physiological
processes in different organisms [10,11]. Adenosine influ-
ences deeply on hypertension, sedation and vessels dilata-
tion [12]. Also, it acts as nerve modulators or as neural
hormones [13].
On the other hand, most of adenosine analogues have
more importance in chemotherapy, cancer, immunology,
virology and parasitology, which could be deaminated by
the enzyme and deactivated through their metabolic path-
way [14]. So, inhibition of ADA can solve mentioned pro-
blems [15,16]. Till now, suggested inhibitors have some
drawbacks such as irreversibility, side effects, high inhib-
ition constant (Ki) and toxicity on the different cells [17].
Moreover, most of existing nucleoside inhibitors not only
have difficulties in their synthesis, but also because of
interfering with function of other enzymes they have been. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Merged pharmacophore from most potent non-nucleoside inhibitor of adenosine deaminase (EHNA) and effective docked
natural products from ZINC data base. Yellow area are demonstrated as Hydrophobic area, gray cycle as exclusion volume regions, red dashes
as H-bond acceptor part and blue dashes as positive region.
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inhibition potency [18].
Natural sources are receiving increasing attention recent
years since they were reported to have a remarkable
spectrum of biological activities including antioxidant, anti-
inflammatory and anti- carcinogenic activities [19-21]. On21
Figure 2 The proposed binding mode of three extracted compound f
within the catalytic site of adenosine deaminase.the other hand, several methods have been raised in
drug discovery such as high throughput screening,
docking and QSAR analysis [22]. The designed com-
pounds were more investigated based on sequential fil-
ters and at last selected compounds were more studied
in biological tests.3
rom in-house library as determined by docking calculations
Table 1 Summary of binding energies, theoretical Ki, IC50
and inhibition constants of new inhibitors for calf
intestinal adenosine deaminase
Compounds ΔG° (kcal/mol) Calculated Ki (μM) IC50 (μM) Ki (μM)
1 −7.02 27 103 63
2 −9.59 0.1 41 20
3 −8.37 15 85 45
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putational techniques such as docking and virtual screen-
ing (VS), help researchers to gain effective compounds in
shorter time and lower costs [23]. The aim of this project
is to develop merged Pharmachophore model based on
the most potent non-nucleoside inhibitor EHNA and nat-
ural products from ZINC data base compounds which
have effective interaction with active site of enzyme. This
model was applied for filtration of effective inhibitors for
ADA from the in-house data base, and their efficiencies
are determined through biological investigations.
Experimental
Chemicals
Adenosine deaminase (from bovine spleen in 3.2 M am-
monium sulfate) was purchased from Sigma (St. Louis,Figure 3 A Michaelis–Menten plot was used to determine
Km and Vmax. The calculated Km was 37.6 μM and Vmax was
15.7 μM min-1 (n = 3).MO, USA). Phosphate buffer 50 mM, pH 7.5, was used
as media which is comprised NaH2PO4 and Na2HPO4
and are from Merck. In addition, other material such as
solvents, were purchased from this company.
Virtual screening
Crystal structure 1KRM from bovine for ADA was
extracted as raw enzyme structure with 80% identity to ap-
plied enzyme in biological tests. Autogride4.2 and Auto-
dock4.2 were used for calculation of grid maps and
docking, respectively. AutoDockTools 1.5.4 was used for
preparing input files. In this study the compounds were
docked on ADA with the grid-box of 126 Å (x, y and z)
with the spacing of 0.375 Å. Docking calculation para-
meters were set to these values: number of Lamarckian
job =100; initial population =100; maximum number of en-
ergy evaluations =25×105; maximum generations =27000;
mutation rate of 0.02; a crossover rate of 0.80. For better
understanding of interactions and access to respective
pharmacophore, LIGSCOT3.0 program was used.
Biological tests
Biological tests have been done on synthesized com-
pounds from Tehran University of Medical Sciences in-
house library. All of biological samples were prepared with
double distilled water. The adenosine stock solution pre-
pared and was used in concentration range of 0.01-0.4
mM. The concentration of enzyme in the assay mixture
50 mM sodium phosphate buffer, was 0.9 nM with a final
volume of 1ml. Enzymatic activities were assayed by UV–
vis spectrophotometry (Shimadzu-3100, Japan) based on
Kaplan Method to follow the decrease in absorbance at
265 nm resulting from the conversion of adenosine to in-
osine [24]. Determination of enzyme activity in the pres-
ence of different concentration of substrate was showed
that the increasing concentration of substrate from 10 to
124 μM enhanced the enzyme activity. But this activity
reached to zero in the higher concentration of substrate
(more than 400 μM). This effect may be due to suicide-
like mechanism in higher concentration of adenosine.
Fluorescence study has been done with fluorescent
spectroscopy (Hitachi MPF-4, Japan), which its cell
length is 1cm. In this method, the exciting wavelength
was adjusted in 290 nm and the emission was studied in
range of 300–400 nm for possible enzyme 3-D structure
changes. In this experiment, different concentrations of
inhibitors (5–100 μM) were investigated in the presence




To validate the method in prediction of binding energy
and possible interaction between ligands and receptor, at
Figure 4 Secondary plot, K0m versus three novel inhibitors in the range of 0–130 μM and in different concentration of substrate
20–124 μM. All experiments performed in 37°C and phosphate buffer, pH=7.5.
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1KRM. After superimposition RMSD <0.1 was gained
and showed that this technique and applied parameters
would be applicable for next predictions.
Extraction of compounds from Tehran University of
Medical Sciences database
In first stage, 8000 natural compounds of ZINC database
were filtered according to lead likeness and were pre-
pared for docking on the ADA. 25% of achieving com-
pounds were filtered with best energy and transmitted to
next stage for docking with higher energy values. After
that, the compounds with acceptable orientation in en-
zyme active site were filtered and binding energy estima-
tion was performed in grid box dimension of 60×60×60
Å. The achieved compounds with best binding energy
include imidazole rings and NO2 group in their position2. As it demonstrated in Figure 1, the related pharmaco-
phore was extracted with Ligandscout software and
merged with extracted pharmacophore from non-
nucleoside potent inhibitor, EHNA (Ki=37 nM) [25].
In next stage, the structures of 540 synthesized com-
pounds from in-house library have been sketched with
Marvin, and were optimized by Hyperchem software.
Then, compounds were filtered by designed merged
pharmacophore and obtained compounds (15 com-
pounds) were docked again and three compounds with
proper fitting in active site and lower binding energies
were extracted Figure 2.The related binding energies are
summarized in Table 1.
Biological assay
Figure 3 shows a Michaelis-Menten plot in the presence
of different concentration of adenosine at pH=7.5 and
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substrate with acceptable Km=37.6 μM.
For accurate determination of kinetic parameters, the
IC50 values were evaluated, and then the enzyme inhibition
was studied in 180 s intervals. The resulted IC50 values are
listed in Table 1. For more inside through mechanism of in-
hibition, kinetic studies were performed and all three com-
pounds show a competitive inhibition mechanism. In a
competitive inhibition; Vmax is unaltered, whereas Km is
increased. The slope of a competitive plot is equal to:




A plot of apparent Km values versus concentration of
inhibitors [I] results to the inhibition constants which is
demonstrated in Figure 4.
To investigate changes in enzyme 3-D structure at dif-
ferent concentration of inhibitors (10–100 μM), the
fluorescence experiments were done in excitation wave-
length of 290 nm, which is due to tryptophan amino
acids in the active site of enzyme Figure 5.
Discussion
According to importance of enzyme inhibition in treat-
ment of some diseases [26], in this research we use a new
approach in better understanding and filtering of specific
ADA inhibitors. After pharmacophore generation, docking
was performed in order to rank the in-house compounds
on the basis of their ability to form favorable interactions
within the active site of ADA. This approach not only
helps us to filter compounds according to their similarity
to most potent non-nucleoside existing inhibitor, but also
helps us to extract compounds with natural template. As1 
Figure 5 The fluorescence spectra of adenosine deaminase at pH=7.5
inhibitors: 10–100 μM.it shown in Figure 2, imidazole derivative compounds
properly stabilize in the binding pocket of ADA with dif-
ferent kinds of interaction such as, hydrophobic, electro-
static, H-bond and π-π stacking. Previously potent
inhibitors with imidazole ring have been reported for
ADA inhibition [27]. From Table 1, the calculated ΔG° en-
ergies are so low which shows effectiveness of compounds
in inhibition. Indeed, resulted Ki from biological tests
improves this subject. Among, compound 2 shows better
interaction with lower binding energy with enzyme −9.59
kcal mol-1.
ADA is inhibited by three filtrated compounds through
competitive mechanism, which is in agreement with docking
studies. This mechanism can attribute to size of molecule
which able compounds penetrate in enzyme active site and
make appropriate interactions. Changing in temperature can
affect on the reaction rate and enzyme activity. As can be
seen in Table 1, resulted Ki from inhibition investigation was
higher than expected from docking studies according to
their binding energies. This is probably due to difference in
temperature was used in biological test, 37°C which enzyme
has maximum activity in, and docking approach which sub-
jected to 25°C according to Gibbs free energy equation.
However, calculated binding energies and experimental Ki
values are following logical trend (r2=0.99). According to
fluorescence intensities for three obtained inhibitors, ADA
shows sever structural changes in lower concentration of 2
(10 μM). Florescence, kinetic study and appropriate inter-
action of compound 2 in enzyme active site have confirmed
its potency as competitive ADA inhibitor.
Conclusion
This study has showed the effective application of docking
and pharmacophore studies in introducing new inhibitors2 3
and T=37°C in the presence of different concentrations of three
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results in extraction of effective compounds from in-
house 540 compounds, and subjected them to experimen-
tal phase for inhibition evaluations. The resulted three
compounds from VS studies showed inhibitory effects
through competitive mechanism on ADA. Compound 2
can be further optimized and used as a lead compound in
new inhibitor design with more potency.
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